Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin + PLD versus carboplatin + PLD in partially platinum-sensitive relapsed ovarian cancer
2010-022949-17Phase 3Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Nov 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Trabectedin + pegylated liposomal doxorubicin with Carboplatin + pegylated liposomal doxorubicin (2 arms). Primary endpoint: Overall survival. Started Nov 2010; status: completed.
02
Drugs
trabectedindoxorubicincarboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2010-022949-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022949-17.